JP2020507566A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507566A5
JP2020507566A5 JP2019542672A JP2019542672A JP2020507566A5 JP 2020507566 A5 JP2020507566 A5 JP 2020507566A5 JP 2019542672 A JP2019542672 A JP 2019542672A JP 2019542672 A JP2019542672 A JP 2019542672A JP 2020507566 A5 JP2020507566 A5 JP 2020507566A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
membered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019542672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/017668 external-priority patent/WO2018148576A1/en
Publication of JP2020507566A publication Critical patent/JP2020507566A/ja
Publication of JP2020507566A5 publication Critical patent/JP2020507566A5/ja
Withdrawn legal-status Critical Current

Links

JP2019542672A 2017-02-10 2018-02-09 ベンゾチオフェンエストロゲン受容体モジュレーター Withdrawn JP2020507566A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762457643P 2017-02-10 2017-02-10
US62/457,643 2017-02-10
US201762460358P 2017-02-17 2017-02-17
US62/460,358 2017-02-17
US201862614279P 2018-01-05 2018-01-05
US62/614,279 2018-01-05
PCT/US2018/017668 WO2018148576A1 (en) 2017-02-10 2018-02-09 Benzothiophene estrogen receptor modulators

Publications (2)

Publication Number Publication Date
JP2020507566A JP2020507566A (ja) 2020-03-12
JP2020507566A5 true JP2020507566A5 (enExample) 2021-03-25

Family

ID=63106724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542672A Withdrawn JP2020507566A (ja) 2017-02-10 2018-02-09 ベンゾチオフェンエストロゲン受容体モジュレーター

Country Status (10)

Country Link
US (3) US10208011B2 (enExample)
EP (1) EP3580223A4 (enExample)
JP (1) JP2020507566A (enExample)
KR (1) KR20190117582A (enExample)
CN (1) CN110461853A (enExample)
AU (1) AU2018217809A1 (enExample)
CA (1) CA3052810A1 (enExample)
IL (1) IL268319A (enExample)
TW (1) TW201835064A (enExample)
WO (1) WO2018148576A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464092B2 (en) 2013-03-15 2016-10-11 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
WO2019157020A1 (en) * 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
CN108203404A (zh) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
CA3109385A1 (en) * 2018-08-16 2020-02-20 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators to treat medical disorders
CN114761082A (zh) 2019-09-30 2022-07-15 日本化学药品株式会社 氮杂环庚烷衍生物
EP4652997A2 (en) 2020-05-19 2025-11-26 Pharmacosmos Holding A/s Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
CN113816892A (zh) * 2021-08-27 2021-12-21 安徽鼎旺医药有限公司 一种醋酸巴多昔芬的合成方法
CN113801094A (zh) * 2021-10-29 2021-12-17 中国药科大学 一种2-羰基苯并噻吩类化合物及其制备方法和用途

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU509682B2 (en) 1975-10-28 1980-05-22 Eli Lilly And Company 2-Aroyl-3-Phenylbenzothiophene Derivatives
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0146243A1 (en) 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5834468A (en) 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
CA2306489A1 (en) 1997-10-03 1999-04-15 Mark Gregory Stocksdale Benzothiophenes
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6060488A (en) * 1998-09-22 2000-05-09 Eli Lilly And Company Benzothiophenes for treating estrogen deficiency
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
CN1450913A (zh) 2000-07-06 2003-10-22 惠氏公司 二膦酸酯、雌激素药物以及任选雌激素的联合应用
WO2002003992A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
AU2001271785A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of statins, estrogenic agents and optionally estrogens
US6358991B2 (en) 2000-07-06 2002-03-19 American Home Products Corporation Methods of treating neuropeptide Y-related conditions
EP1990051A1 (en) 2000-07-06 2008-11-12 Wyeth Combinations of SSRI and estrogenic agents
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
WO2002003986A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating breast disorders
AU2001271781A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
AU2001271782A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
JP2004502734A (ja) 2000-07-06 2004-01-29 ワイス 一酸化窒素シンターゼ活性の増強方法
PT1318837E (pt) 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ(muri)の阻害剤としての縮合複素環
FR2862646B1 (fr) 2003-11-20 2006-02-24 Merck Sante Sas Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
EP1846397A1 (en) 2005-01-21 2007-10-24 Janssen Pharmaceutica N.V. Novel heterocyclic benzoy[c]chromene derivatives useful as modulators of the estrogen receptors
CA2597447C (en) 2005-02-14 2014-03-25 Bionomics Limited Novel tubulin polymerisation inhibitors
CA2640678C (en) 2006-02-03 2015-03-31 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
ES2436028T3 (es) 2006-06-23 2013-12-26 Radius Health, Inc. Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno
EP1947085A1 (en) 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
CA2693207A1 (en) 2007-07-25 2009-01-29 F. Hoffmann-La Roche Ag Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators
WO2010093578A1 (en) 2009-02-10 2010-08-19 Glaxo Group Limited Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
US8809382B2 (en) 2009-05-04 2014-08-19 The Royal Institution For The Advancement Of Learning/Mcgill University 5-oxo-ETE receptor antagonist compounds
CA2800673A1 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
CA2819299A1 (en) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
EA029559B1 (ru) 2011-12-14 2018-04-30 Серагон Фармасьютикалс, Инк. Фторированные модуляторы рецепторов эстрогенов и их применение
CN104169266A (zh) 2011-12-16 2014-11-26 奥乐玛药物股份有限公司 新的苯并吡喃化合物、其组合物和用途
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Rtk阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
JP6154887B2 (ja) 2012-03-20 2017-06-28 セラゴン ファーマシューティカルズ,インク. エストロゲン受容体モジュレーターおよびその使用
ES2774935T3 (es) 2012-10-24 2020-07-23 Univ Illinois Composiciones y métodos para tratar trastornos médicos relacionados con estrógeno
WO2014066695A1 (en) 2012-10-24 2014-05-01 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating estrogen-related medical disorders
CN105008343B (zh) 2013-02-19 2017-12-08 诺华股份有限公司 作为选择性雌激素受体降解剂的苯并噻吩衍生物及其组合物
EP2970130A4 (en) 2013-03-14 2016-08-03 Seragon Pharmaceuticals Inc MODULATORS OF POLYCYCLIC STROGEN RECEPTORS AND USES THEREOF
UY35590A (es) 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
KR20160021277A (ko) 2013-06-19 2016-02-24 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조절제 및 이의 용도
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
GB201311888D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
CA2940576A1 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
AU2015228860A1 (en) 2014-03-13 2016-09-08 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
ES2819448T3 (es) 2014-12-18 2021-04-16 Hoffmann La Roche Tetrahidro-pirido[3,4-b]indoles como moduladores del receptor de estrógenos y usos de los mismos
WO2016097073A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
WO2016189011A1 (en) 2015-05-26 2016-12-01 F. Hoffmann-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
RU2745742C1 (ru) 2015-10-01 2021-03-31 Олема Фармасьютикалз, Инк. ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
WO2017056115A1 (en) 2015-10-03 2017-04-06 Sun Pharma Advanced Research Company Limited Novel n-aryl containing fused heterocyclic compounds
EP3359527A1 (en) 2015-10-07 2018-08-15 H. Hoffnabb-La Roche Ag Process for the preparation of (e)-3-(4-((e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
EA034131B1 (ru) 2015-10-27 2020-01-09 Сан Фарма Адвансед Ресёрч Компани Лимитед Гетероциклические антиэстрогены
CN108495628B (zh) 2015-12-09 2022-01-11 伊利诺伊大学评议会 苯并噻吩基选择性雌激素受体下调剂
MX386677B (es) 2016-02-15 2025-03-19 Sanofi Sa Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos

Similar Documents

Publication Publication Date Title
JP2020507566A5 (enExample)
JP2018516238A5 (enExample)
JP2018519245A5 (enExample)
TWI385160B (zh) 用於治療增生性疾病的化合物
JP2018515438A5 (enExample)
JP2018530549A5 (enExample)
JP2014525438A5 (enExample)
JP2014521688A5 (enExample)
JP2015516434A5 (enExample)
JP2016523974A5 (enExample)
JP2018138577A5 (enExample)
JP2015517574A5 (enExample)
JP2017526677A5 (enExample)
RU2018127315A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний
JP2017502940A5 (enExample)
JP2018507877A5 (enExample)
JP2017517565A5 (enExample)
JP2016121196A5 (enExample)
RU2016134751A (ru) Соединения
JP2018515492A5 (enExample)
JP2016503799A5 (enExample)
JP2017519781A5 (enExample)
JP2018528942A5 (enExample)
JP2019501130A5 (enExample)
JP2012525393A5 (enExample)